Engineering an in vivo charging station for CAR-redirected invariant natural killer T cells to enhance cancer therapy - PubMed
6 hours ago
- #biomimetic platform
- #CAR-iNKT cells
- #cancer immunotherapy
- Invariant natural killer T (iNKT) cells are promising for cancer immunotherapy due to their allogeneic potential and tumor-homing capacity.
- CAR-redirected iNKT (CAR-iNKT) cells face limitations like insufficient activation and poor persistence in the tumor microenvironment.
- The iNKT cell-targeted microparticle recruitment and activation system (iMRAS) is a biomimetic platform designed to locally recruit, activate, and expand CAR-iNKT cells in vivo.
- iMRAS acts as an 'in vivo charging station,' enhancing CAR-iNKT cell functionality, persistence, and tumor control in preclinical models.
- The technology has potential to overcome current limitations in solid tumor therapies and advance CAR-iNKT cell-based immunotherapy.